Full-Time

Senior / Executive Director

Analytical Development CMC

Iambic Therapeutics

Iambic Therapeutics

51-200 employees

AI-driven discovery for oncology and neurology

Compensation Overview

$224k - $310k/yr

Remote in USA + 1 more

More locations: San Diego, CA, USA

Hybrid

Remote role with travel up to 15% domestically and internationally.

Bachelor's, Master's, PhD

Category
Biology & Biotech (2)
,
Required Skills
GMP

Get referred to Iambic Therapeutics

See people who can refer or advise you

Requirements
  • A Ph.D. in Analytical Chemistry or a related field with 12 or more years of experience in the pharmaceutical or biotechnology industry, or an M.Sc. with 14 or more years of experience, or a B.Sc. with 17 or more years of experience.
  • Extensive hands-on experience in analytical method development, transfer, troubleshooting, and validation for small-molecule drug substance and drug product across early- and late-stage development.
  • Strong experience developing phase-appropriate analytical control strategies, including specifications, impurity and degradation-product control, reference standards, stability-indicating methods, dissolution, and product characterization.
  • Demonstrated experience supporting early- and late-stage development and regulatory filings, including Investigational New Drug applications and Investigational Medicinal Product Dossiers; experience with New Drug Applications or Marketing Authorisation Applications is preferred.
  • Proven success leading Analytical Development and Quality Control activities through external Contract Development and Manufacturing Organizations, including technical oversight, issue resolution, and management of multiple programs and partners.
  • In-depth knowledge of current Good Manufacturing Practice laboratory operations, global regulatory expectations, and relevant International Council for Harmonisation guidance.
  • Strong experience with analytical methods for enabling formulations and conventional oral solid dosage forms.
  • Proven leadership experience building collaborative, high-performing teams and working effectively across Drug Substance, Drug Product, Quality, Regulatory CMC, Clinical Supply, and other functions.
  • Ability to communicate technical issues, risks, and recommendations to internal stakeholders, external partners, and health authorities in written and verbal formats.
  • Ability to travel up to 15% domestically and internationally.
Responsibilities
  • Lead drug substance and drug product analytical strategy and scientific oversight across characterization, impurity and degradation-product control, reference standards, comparability, and stability, including shelf-life and retest assessment and emerging stability risks.
  • Lead analytical method development, validation, transfer, lifecycle management, and troubleshooting across drug substance and drug product, ensuring methods are fit for purpose, scientifically sound, and aligned with regulatory expectations.
  • Oversee Quality Control testing and data review for release and stability, including out-of-specification and out-of-trend investigations, deviations, root-cause assessment, corrective and preventive actions, and resolution of analytical issues.
  • Establish scientifically justified specifications and analytical acceptance criteria based on product and process understanding, batch history, stability data, and stage of development.
  • Provide analytical leadership for dissolution and product-performance testing, including development of Quality Control and discriminatory methods for oral drug products.
  • Lead the outsourced analytical and Quality Control network, including partner selection, technical oversight, governance, issue resolution, and performance management.
  • Ensure analytical activities support program timelines and manufacturing readiness through close partnership with Drug Substance, Drug Product, Quality, Regulatory CMC, Clinical Supply, and other cross-functional teams.
  • Lead analytical CMC support for global regulatory submissions and health-authority interactions, including authoring and reviewing relevant Module 3 content, specifications and justifications, analytical methods, stability sections, and responses to regulatory queries.
  • Recruit, lead, coach, and develop team members; oversee functional resource planning and budget proposals; and foster a collaborative, high-performing environment aligned with organizational goals.
Desired Qualifications
  • Experience with New Drug Applications or Marketing Authorisation Applications.

Iambic Therapeutics develops therapeutics using an AI-driven discovery platform, focusing on oncology and neurological diseases in clinical-stage programs. The platform combines advanced AI models with automated experiments to predict molecular properties faster and with less data, speeding identification and optimization of drug candidates. It differentiates itself by maintaining an in-house pipeline alongside strategic pharmaceutical partnerships to advance programs and earn milestones and royalties. The goal is to bring new therapies to patients by accelerating discovery and development through AI and automation.

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$303M

Headquarters

San Diego, California

Founded

2019

Get referred to Iambic Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Takeda’s February 2026 deal provides upfront, research, and technology-access payments.
  • Bayer joined June 2026, expanding non-dilutive validation beyond oncology into broader drug discovery.
  • Iambic raised over $100 million in November 2025, supporting runway into 2028.

What critics are saying

  • Takeda’s billion-dollar value depends on milestones; failure in programs kills economics.
  • IAM1363 remains single-asset clinical proof; Phase 1b setbacks would crush credibility.
  • Big pharma can internalize AI discovery, and Bayer or Takeda can switch vendors.

What makes Iambic Therapeutics unique

  • NeuralPLexer and Enchant anchor Iambic’s AI stack for structure and endpoint prediction.
  • Takeda chose Iambic in February 2026, validating platform value with blue-chip pharma.
  • IAM1363 reached Phase 1/1b in two years, versus six-year industry averages.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Company Match

Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

-2%
Intelligence360 News
Dec 3rd, 2025
Iambic Therapeutics raises $125M in new funding

Iambic Therapeutics has filed a notice with the US Securities and Exchange Commission for an exempt offering to raise $125 million in new funding. The filing was made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act, which allows companies to sell securities without registration under the Securities Act of 1933. Federal securities law requires such notices to be filed within 15 days after the first sale of securities in the offering. No additional details about the funding round, including investors or valuation, were disclosed in the filing.

Iambic Therapeutics
Nov 11th, 2025
Iambic Raises Over $100 Million in an Oversubscribed Round to Advance its Portfolio of AI-Discovered Therapeutics and Leading Platform Technologies

San Diego, CA – Nov. 10, 2025 – Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced raising over $100 million in an oversubscribed financing round with balanced support from new and existing investors, including Abingworth, Alexandria Venture Investments, Alumni Ventures, ARK, Ascenta, Catalio, Everbright Biofund, Freeflow Ventures, Illumina Ventures, Mubadala, Pegasus Tech Ventures, Qatar Investment Authority, Regeneron Ventures, Sequoia, Tao Capital Partners, Terra Magnum Capital Partners, Wilson Sonsini Goodrich & Rosati, and others.

Endpoints News
Nov 10th, 2025
Iambic Therapeutics raises $100M funding

Iambic Therapeutics has secured over $100 million in a new funding round, as revealed by CEO Tom Miller. The investment comes from ARK and Regeneron, highlighting significant financial backing for the San Diego-based biotech company.

EntArabi
Jun 20th, 2024
Iambic Therapeutics raises $50M in Series B

Iambic Therapeutics, a US-based biotech company, raised $50 million in an expanded Series B funding round led by Mubadala Capital. The round included Qatar Investment Authority, Exor Ventures, and existing investors like Abingworth, Illumina Ventures, Nexus Venture Partners, Coatue, and Tao Capital Partners. This funding is part of a previous $100 million Series B round closed in October 2023. The funds will be used to advance Iambic's clinical and preclinical programs.

Pharmaceutical Business Review
Jun 19th, 2024
Iambic secures $50m to bolster clinical oncology programme pipeline

Iambic Therapeutics has secured $50m in its Series B extension financing round to bolster its pipeline comprising clinical oncology programmes.